Clinical trial
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab…
NCT06390059 · NovoCure Ltd., Industry · Active, not recruiting
Key facts
| NCT number | NCT06390059 |
|---|---|
| Title | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma |
| Official title | PANOVA-4: Pilot, Single Arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) |
| Lead sponsor | NovoCure Ltd., Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Pancreatic Ductal Adenocarcinoma |
| Intervention type | Device, Drug |
| Interventions | Tumor Treating Fields, Atezolizumab, Gemcitabine, nab-paclitaxel |
| Enrollment | 84 |
| Start date | Aug 28, 2023 |
| Primary completion | Nov 27, 2025 |
| Completion | Nov 27, 2025 |
| First posted | Apr 29, 2024 |
| Last update posted | Apr 30, 2025 |
| Countries | Czechia, Germany, Spain, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: